Clinical Trial

mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Trial Details
NCT Number NCT07557602
Lead Sponsor Vaccine Company, Inc.
Conditions EBV
Enrollment 45 participants
Start Date 2026-05-04
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-29